Pharsight

1. Zubsolv patents expiration

Application	Filing Date	Opposition Party	Legal Status

EP12775283A	2015-12-04	Generics (U.K.) Limited	Opposition procedure closed
EP07824784A	2014-08-06	Generics [UK] Limited	Opposition rejected

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8658198	OREXO US INC	Non-abusable pharmaceutical composition comprising opioids	Dec, 2027 (4 years from now)
US8470361	OREXO US INC	Non-abusable pharmaceutical composition comprising opioids	May, 2030 (6 years from now)
US11020388	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US11020387	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US10946010	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US8940330	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US9439900	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US9259421	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US10874661	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)
US11433066	OREXO US INC	Abuse-resistant pharmaceutical composition for the treatment of opioid dependence	Sep, 2032 (8 years from now)

Drugs and Companies using BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE ingredient

Market Authorisation Date: 03 July, 2013

Treatment: Sublingual or buccal administration of a pharmaceutical composition comprising buprenorphine and naloxone; Sublingual administration of a pharmaceutical composition comprising buprenorphine and naloxo...

Dosage: TABLET;SUBLINGUAL

Strength	Submission Date	ANDA(s) Filed	Last patent expiry
1.4 mg/0.36 mg and 5.7 mg/1.4 mg	22 Oct, 2013	1	22 May, 2030
8.6 mg/2.1 mg and 11.4 mg/2.9 mg	24 Jul, 2015	1	18 Sep, 2032
2.9 mg/7.1 mg	21 Dec, 2015	1	18 Sep, 2032
0.7 mg/0.18 mg	04 May, 2017	1	18 Sep, 2032

Strength	Dosage	Availability
EQ 0.7MG BASE;EQ 0.18MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 1.4MG BASE;EQ 0.36MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 2.9MG BASE;EQ 0.71MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 5.7MG BASE;EQ 1.4MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 8.6MG BASE;EQ 2.1MG BASE	TABLET;SUBLINGUAL	Prescription
EQ 11.4MG BASE;EQ 2.9MG BASE	TABLET;SUBLINGUAL	Prescription